Description
Anti-Sclerostin Antibody, Highly Galactosylated (BioBet-GA-012ZP) is a human IgG1 antibody against Sclerostin which contains with a high level of galactosylation.
Antibody Indication
Severe Eosinophilic Asthma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Sclerostin antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SOST
Full Name
sclerostin
Background
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
Alternative Names
SOST; sclerostin; CDD; VBCH; SOST1
Gene ID
50964
UniProt ID
Q9BQB4
Cellular Localization
Extracellular region or secreted
Genecards
13771
Involvement in Disease
Its related pathways are Signaling by GPCR and Signaling by Wnt.
Related Pathways
Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
Field of research
Glycosylation at Asn53 and Asn175
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-GA-012ZP
Description
Romosozumab is a humanized monoclonal antibody that targets sclerostin. It is used in postmenopausal women with a high risk of fracture and in patients who have failed treatment or are intolerant to other osteoporosis treatments. Osteoporosis in the treatment of osteoporosis. Studies have shown that the drug can increase bone formation and reduce bone resorption in postmenopausal women with low bone density. Romolimumab is approved for medical use in the United States in 2019. Romosozumab is sold in the United States by Amgen under the trade name Evinity.
Antibody Indication
Osteoporosis
Osteoporosis
Autoimmune diseases
Osteoporosis
